• Margarita Udall, Jack Mardekian, and Javier Cabrera.
• Pfizer Inc., 235 East 42nd Street, New York, NY 10017, U.S.A. Margarita.Udall@pfizer.com
• Pain Pract. 2013 Jul 1;13(6):476-84.

ObjectiveTo characterize patient populations with favorable costs after the initiation of pregabalin for the treatment of painful diabetic peripheral neuropathy (pDPN) relative to duloxetine, gabapentin, and amitriptyline.MethodsPatients were identified from MarketScan having ≥ 1 claim for pDPN (ICD-9-CM codes 250.6 or 357.2) within 60 days of first prescription (index) for pregabalin, duloxetine, gabapentin, or amitriptyline in 2008 and continuous enrollment 12 months pre- and postindex. Pregabalin patients were propensity-score-matched to each comparator. Using cutoff values ≥ 80% proportion of days covered (PDC) and ≥ 65 years for age, pre- to postindex changes in healthcare costs were estimated for pregabalin vs. comparators.ResultsOf 987 patients initiated on pregabalin, 349 matched to duloxetine; 987 to gabapentin; 276 to amitriptyline. The pre- to postindex changes in total healthcare costs were similar between cohorts: $3272 with pregabalin vs. $2290 with duloxetine (P = 0.5280); $3687 with pregabalin vs. $5498 with amitriptyline (P = 0.5863); $3869 with pregabalin vs. $4106 with gabapentin (P = 0.8303). For the high-age/high-PDC population, the pre- to postindex differences in mean total costs were significantly lower with pregabalin (P < 0.001) relative to comparators ($3573 vs. $8288 for duloxetine; $1423 vs. $3167 for gabapentin; $2285 vs. $6160 for amitriptyline).ConclusionsThe association of lower total costs among older individuals with pDPN who maintain high adherence to pregabalin therapy relative to key comparators suggests a pharmacoeconomic advantage of pregabalin in this population combined with a need for strategies promoting adherence.© 2012 The Authors Pain Practice © 2012 World Institute of Pain.

22 keywords...

hide…